Arthur Franken - Gilde Healthcare

team
Venture&Growth

All team members
Arthur Franken
General Partner Healthtech/Therapeutics
Venture&Growth
The Netherlands

Arthur Franken

General Partner - Healthtech/Therapeutics
Venture&Growth

Arthur Franken joined Gilde in 2001 and was part of the founding team of Gilde Healthcare. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Amphista Therapeutics, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx, FIRE1 and Pieris (IPO on NASDAQ).

He represents Gilde on the boards of Calypso, Levicept, Moximed and Noema Pharma and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.

Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Geoff Pardo

General Partner Healthtech
Venture&Growth
Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde's investments in North America. He led the investments in Ablative Solutions, Inari...

Sanne de Jongh

Investment Manager Therapeutics
Venture&Growth
Sanne de Jongh joined Gilde Healthcare in 2017 and focuses on the biopharmaceutical sector. She is involved in deal sourcing, assessment of investment cases and portfolio management. She represents Gilde on the board of Calypso...

Michael R. Jaff, DO

Operational Partner
Michael R. Jaff, DO is the Chief Medical Officer and Vice-President of clinical affairs, technology and innovation at Boston Scientific Corporation. A professor of medicine at Harvard Medical School, Dr. Jaff was the President of...